Suppliers / Shandong Jincheng Kunlun Pharmaceutical

Shandong Jincheng Kunlun Pharmaceutical

China Updated 9 July 2026

Shandong Jincheng Kunlun Pharmaceutical is an API manufacturer based in China. It holds 2 active US drug master files across a filed portfolio of 2 molecules. Its GMP standing is certified by US FDA. Its most recent recorded inspection, by US FDA, closed on 5 December 2025 as VAI.

2
active US DMFs
0
valid CEPs
1
registered plants 1 with an FDA FEI number
0
filings across 0 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 5 December 2025 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
China, China 3024002685

What they file, and where

Molecule Regulators Docs
Tofacitinib SFDA (Saudi Arabia), US FDA 2
Posaconazole US FDA 1

Also appears on these molecule pages

Posaconazole API Tofacitinib API

Filings and GMP by regulator

Regulator Filings GMP certificates
US FDA None 1

Questions about Shandong Jincheng Kunlun Pharmaceutical

Does Shandong Jincheng Kunlun Pharmaceutical hold a US DMF or a CEP?
Shandong Jincheng Kunlun Pharmaceutical holds 2 active US drug master files. A drug master file is a submission to the FDA describing how an ingredient is made; a CEP is the EDQM's certificate that the substance meets its European Pharmacopoeia monograph. Both are filings rather than approvals.
Is Shandong Jincheng Kunlun Pharmaceutical FDA-registered?
One site operated by Shandong Jincheng Kunlun Pharmaceutical carries an FDA establishment identifier (FEI), which means it is registered with the FDA as a drug establishment. Registration is not the same as approval or inspection clearance.
How did Shandong Jincheng Kunlun Pharmaceutical's last inspection go?
The most recent inspection on record closed on 5 December 2025 as VAI (Voluntary Action Indicated: issues were found but did not warrant regulatory action). 1 inspection is on file.
Where does Shandong Jincheng Kunlun Pharmaceutical manufacture?
1 registered site is on record, in China (China). Every site is listed on this page with the register it came from.
What does Shandong Jincheng Kunlun Pharmaceutical make?
2 molecules are on record against Shandong Jincheng Kunlun Pharmaceutical, including Tofacitinib and Posaconazole. Each links through to that molecule's full manufacturer list.
Which regulators recognise Shandong Jincheng Kunlun Pharmaceutical's GMP?
Current GMP certificates are on record from US FDA. GMP recognition covers the manufacturing site, separately from any filing on the substance itself.

Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.

Comparing suppliers?

Choose your molecules and target markets. Shandong Jincheng Kunlun Pharmaceutical comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was VAI, on 5 December 2025.

Comparable suppliers

MSN Laboratories shares 2 molecules Dr Reddy's Laboratories shares 2 molecules Olon shares 2 molecules Honour Lab shares 2 molecules Apotex shares 2 molecules

Ranked by shared active ingredients where we have them, otherwise by country and comparable credentials.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates